Adverse outcome in patients who undergo curative surgical resection of rectal and colonic carcinoma results from local recurrence or emergence of initially occult distant metastases. Molecular methodologies offer new approaches to evaluate the status of resection margins and the metastatic phenotype in primary tumors. Polymerase chain reaction with cloning into bacteriophage vectors for further expansion permits detection of DNA from one mutant cancer cell among thousands of non-neoplastic cells. Representational difference analysis (RDA) provides the ability to identify and characterize amplifications which may be prognostic markers in tumors. The hypotheses to be tested in this project are: l. Microscopically occult neoplastic cells at the surgical margins of rectal cancer patients can be detected by molecular genetic analysis, thereby serving as markers for recurrence. 2. Amplified genes in primary colorectal carcinomas are markers for poor prognosis.
Our specific aims for this project are to: l. Evaluate mutations in ras and p53 genes in margin tissue and pelvic irrigation specimens collected after curative resection of rectal carcinomas. Molecular genetic results will be related to histopathologic findings, recurrence, and survival. 2. Apply representational difference analysis (RDA) to pairs of matched metastatic and non-metastatic primary colorectal carcinomas. RDA probes detecting amplifications will be cloned, mapped, and used to search for target genes. The amplifications will be evaluated as prognostic markers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA062924-08S2
Application #
6502411
Study Section
Project Start
2001-05-04
Project End
2002-06-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kuboki, Yuko; Fischer, Catherine G; Beleva Guthrie, Violeta et al. (2018) Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. J Pathol :
Zhang, Jiajia; Quadri, Shafat; Wolfgang, Christopher L et al. (2018) New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 6:
Hata, Tatsuo; Suenaga, Masaya; Marchionni, Luigi et al. (2018) Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. Am J Pathol 188:1723-1733
Noë, Michaël; Rezaee, Neda; Asrani, Kaushal et al. (2018) Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. Am J Pathol 188:1530-1535
Schunke, Kathryn J; Rosati, Lauren M; Zahurak, Marianna et al. (2018) Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Adv Radiat Oncol 3:42-51
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Staedtke, Verena; Bai, Ren-Yuan; Kim, Kibem et al. (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273-277
Deng, Yang; Tu, Huakang; Pierzynski, Jeanne A et al. (2018) Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 92:20-32
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772

Showing the most recent 10 out of 883 publications